ProQR Therapeutics (PRQR) Cash from Financing Activities (2013 - 2022)

ProQR Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $14.0 million for Q4 2022.

• In Q4 2022, Cash from Financing Activities fell 54.44% year-over-year to $14.0 million; the TTM figure through Dec 2022 stood at -$31.1 million (down 119.11% YoY), while the FY2025 annual figure was -$2.1 million, down 102.85% from the prior year.
• Cash from Financing Activities came in at $14.0 million for Q4 2022 at ProQR Therapeutics, up from -$44.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $100.4 million in Q2 2021 to a low of -$44.1 million in Q3 2022.
• A 5-year average of $15.1 million and a median of $388399.7 in 2020 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities soared 1454193237.85% in 2018 and tumbled 258.77% in 2022, its largest moves.
• ProQR Therapeutics' Cash from Financing Activities stood at $1108.3 in 2018, then jumped by 5013920.83% to $55.6 million in 2019, then tumbled by 99.58% to $234881.1 in 2020, then soared by 13022.88% to $30.8 million in 2021, then tumbled by 54.44% to $14.0 million in 2022.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $14.0 million, -$44.1 million, and -$380939.2 for Q4 2022, Q3 2022, and Q2 2022 respectively.

Peer Comparison